Of the three stage IV melanoma patients who developed progress, one patient received additional immune checkpoint combination therapy with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) and developed a complete response until the end of the observation period (31 December 2021). This evidence concerns the gene PDCD1 and melanoma.